Clinical trial NCT05468554: Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
Official title: Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Thyroid Cancer
Lead sponsor: Medical University of Bialystok
Sponsor class: OTHER
Collaborators: name: Medical Research Agency, Poland
First posted: 2022-07-21
Enrollment: 160
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Arm A - patients qualified to receive metformin and 131I treatment, arm B - patients receiving placebo and 131 I treatment. Arm C- observation group, patients undergoing thyroidectomy, characterized by low risk of disease progression, in this case, not qualified for the 131I treatment.
Primary purpose: TREATMENT

Brief summary: This study is aimed to investigate the metformin effect on the fertility of women treated with 131 I for thyroid cancer

Detailed description: One of the most common types of endocrine cancer, especially in young women, is thyroid cancer. More than 90% of all thyroid cancers are differentiated thyroid cancers (DTC), including papillary thyroid cancer (PTC) and follicular cancer. Papillary thyroid cancer is considered as indolent tumour as progression free survival is 10 years of 98%. As per current knowledge and basing on current literature most of the PTC are considered to be low incidence of recurrence or metastasis, however, there are more invasive/aggressive types with very specific pathological and molecular characteristics. The aggressive variants of PTC were strictly associated with higher rates of extrathyroid extension, multifocality, and nodal and distant metastasis. Thyroidectomy followed by radioactive iodine 131 (131I) therapy, in higher stages of PTC disease to ablate residual thyroid cancer or treat metastases, significantly increase survival Metformin (1,1-dimethylbiguanide) is an oral antihyperglycemic drug. Orally administered metformin is absorbed into the blood in 40-60% of the drug dose. Maximum blood levels are reached after approximately 2.5 hours for the immediate-release formulation and 7 hours for the prolonged-release tablets. It is not metabolised in the liver, however, it is excreted unchanged by the kidneys, mainly through the renal tubules. Metformin is used in patients with type 2 diabetes and prediabetes as well as in insulin resistant state and in women with polycystic ovary syndrome (PCOS). Metformin works by lowering level of glucose in the blood by lowering its production by the liver and increasing the sensitivity to insulin by muscle and fat tissue. It also has a beneficial effect on serum lipids by reducing the concentration of triglycerides, total cholesterol, LDL-cholesterol and VLDL. Additionally, this drug has also several other biological effects such as anti-inflammatory, anticancer, hepatoprotective, cardioprotective, otoprotective, radioprotective and radio-sensitising.

Currently there is also a large evidential material for effectiveness of metformin therapy in re-establishing of reproductive functions and fertility in women with polycystic ovary syndrome.

Having proved the metformin restore of ovulation in PCOS and has antioxidant properties there are indications that metformin can be a therapy which will helps to maintain ovary follicle number on acceptable level. At present, there are no performed studies concerned on the evaluation of the potential beneficial effect of metformin application impact on fertility parameters in the group of women treated with 131I. Therefore, the proposed study will assess the effect of metformin intervention on the indirect parameters of fertility of women treated with 131I for papillary thyroid cancer

Eligibility criteria: Inclusion Criteria:

* Female subjects in reproductive age \>18 \<45.
* Subjects with diagnosed papillary thyroid carcinoma with various pathological, stage TNM (I-II).
* Subjects not treated with 131I.
* Serum TSH concentration 0.1-4.9 mU/l.
* Willingness to comply with protocol procedures.

Exclusion Criteria:

* Hypersensitivity to metformin.
* Subjects with polycystic ovarian syndrome or other diseases of the ovaries (primary / secondary ovarian failure).
* Subjects taking metformin during last week.
* Subjects with liver malfunction and abnormal hepatitis marker results (ALT and AST activity \>3ULN.
* Subjects with eGFR below 45ml/min/1.73m2.
* Subjects with lactic acidosis or having history of metabolic acidosis.
* Subjects with serum AMH concentration below lower range norm.
* Subjects with history of congestive heart disease NYHA stage III/IV.
* Subjects with acute myocardial ischemia (CCS 3-4).
* Subjects with history of sepsis or severe infection.
* Subject with lung disease (uncontrolled asthma based on GINA 2000 Guidelines and COPD GOLD ≥ 3 stage).
* Positive result of pregnancy test or pregnancy planned during the study.
* Alcohol or other substance dependent syndromes.
* BMI \<18.5 kg/m2.
* Accompanying diseases with poor prognosis in the opinion of the researcher.
* As per Investigator (or his designee) judgement, subject cannot participate in the study due to reasons (i.e. medical, psychiatric and/or social reason).
* Unreliability or lack of cooperation.

Primary outcomes:
measure: Changes in AMH, Inhibin B and FSH levels due to the action of metformin
timeFrame: 4 years
Secondary outcomes:
measure: Assessment of the effect of metformin on the parameters of oxidative stress
timeFrame: 4 years
measure: The evaluate of difference in serum concentration of selected parameters of apoptosis
timeFrame: 4 years
measure: The evaluate of difference in expression in selected microRNA
timeFrame: 4 years
Other outcomes:
Locations:
city: Bialystok
country: Poland
facility: Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of Bialystok
Study officials:
affiliation: Medical University of Bialystok
name: Agnieszka Adamska, Assoc.Prof.
role: PRINCIPAL_INVESTIGATOR
References: